7 completed, 4 terminated, 2 recruiting, 1 active not recruiting. 5 Phase 2, 4 Phase 1, 4 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Carcinoma, Adenosquamous: new trials by email Literature Review of Carcinoma, Adenosquamous trials Research Report on Carcinoma, Adenosquamous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors ESK981 - Pancreatic Adenocarcinoma, Adenosquamous Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 17 | 2024-04-19 | 2026-05-14 |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer Standard treatment: Control arm, Experimental arm - Cervical Carcinoma, Adenocarcinoma | Phase 3 | Recruiting | Institut Claudius Regaud | 510 | 2023-12-20 | 2026-10-13 |
| A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination - Lung Cancer, Small Cell Lung Cancer | Completed | Creative Biosciences (Guangzhou) Co., Ltd. | 1564 | 2022-02-25 | 2025-03-21 | |
| Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer Cabozantinib 40 MG oral once a day, Pembrolizumab 200 mg IV every 3 weeks - Cervical Cancer, Recurrent Cervical Cancer | Phase 2 | Terminated | University of South Alabama | 5 | 2020-04-16 | 2022-06-07 |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2017-10-11 | 2023-07-24 |
| The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial Metformin, Cisplatin, FAZA - Uterine Cervical Neoplasms, Squamous Cell Carcinoma | Phase 2 | Completed | University Health Network, Toronto | 16 | 2015-05-21 | 2021-04-21 |
| Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Axalimogene filolisbac - Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer | Phase 1 | Completed | Advaxis, Inc. | 12 | 2015-03-04 | 2024-05-20 |
| T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Aldesleukin, Fludarabine, Cyclophosphamide - Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 85 | 2014-10-23 | 2026-10-20 |
| Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Extraperitoneal laparoscopic lymphadenectomy (EPLND), Chemoradiation - Cervical Squamous Cell Carcinoma, Adenosquamous Carcinoma | Phase 3 | Completed | M.D. Anderson Cancer Center | 28 | 2011-08-01 | 2021-02-03 |
| Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial) CT Abdomen and Pelvis scan + whole body PET-CT scan, CT Abdomen and Pelvis scan - Cervical Cancer, Squamous Cell Carcinoma | Not applicable | Completed | Ontario Clinical Oncology Group (OCOG) | 171 | 2010-04-01 | 2020-01-29 |
| Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology CP-751,871 (Figitumumab), Carboplatin, Paclitaxel - Carcinoma, Squamous Cell, Carcinoma, Adenosquamous | Phase 3 | Terminated | Pfizer | 681 | 2008-04-01 | 2014-01-13 |
| Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck Abraxane, Erbitux, Carboplatin - Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 29 | 2007-11-01 | 2017-11-13 |
| Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck Panitumumab, Carboplatin, Paclitaxel - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Completed | Massachusetts General Hospital | 34 | 2006-04-01 | 2017-03-01 |
| Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer hysterectomy - Stage IB2 Cervical Cancer, Stage II Cervical Cancer | Phase 3 | Terminated | UNICANCER | 61 | 2003-05-01 | 2011-06-01 |
Adenocarcinoma (10) · Carcinoma, Squamous Cell (9) · Uterine Cervical Neoplasms (7) · Carcinoma (4) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Large Cell (2) · Lung Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenoma, Islet Cell (1) · Bronchitis (1) · Bronchitis, Chronic (1) · Carcinoma, Small Cell (1) · Gastro-enteropancreatic neuroendocrine tumor (1)
Neoplasms, Complex and Mixed (14) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms by Site (13) · Neoplasms, Glandular and Epithelial (13) · Carcinoma (10) · Neoplasms, Squamous Cell (8) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Urogenital Diseases (7) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Urogenital Neoplasms (6) · Uterine Cervical Diseases (6)
Carboplatin (3) · Paclitaxel (3) · Cisplatin (2) · Cyclophosphamide (2) · Radiotherapy, Intensity-Modulated (2) · aldesleukin (2) · fludarabine (2) · 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one (1) · Albumin-Bound Paclitaxel (1) · Cetuximab (1) · Chemoradiotherapy (1) · Docetaxel (1) · Fluorouracil (1) · Hysterectomy (1) · Interleukin-2 (1)
Advaxis, Inc. (1) · Creative Biosciences (Guangzhou) Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institut Claudius Regaud (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · National Cancer Institute (NCI) (1) · Ontario Clinical Oncology Group (OCOG) (1) · Pfizer (1) · UNICANCER (1) · University Health Network, Toronto (1) · University of Michigan Rogel Cancer Center (1) · University of South Alabama (1)
United States (8) · Canada (3) · France (3) · Czechia (2) · Italy (2) · Spain (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · China (1) · Finland (1) · Germany (1) · Greece (1)
Anthony Fyles, MD (1) · Ben Creelan, M.D. (1) · Douglas Coyle, PhD (1) · Greg Pond, PhD (1) · James C Yang, M.D. (1) · Karen Gulenchyn, MD (1) · Kathy Han, M.D. (1) · Laiyu Liu, PhD (1) · Laurie Elit, MD (1) · Lei Zheng, PhD (1) · Lori J. Wirth, MD (1) · Mark Levine, MD (1) · Michael M. Frumovitz, MD, MPH (1) · Mostafa Atri, MD (1)
PMID 24888810, PMID 30646153, PMID 30714987, PMID 34385708, PMID 38468440, PMID 41332393